Literature DB >> 17082899

Response to influenza vaccine in people with non-protective HI antibody titers.

Vincenzo Baldo, Tatjana Baldovin, Annarosa Floreani, Michele Minuzzo, Renzo Trivello.   

Abstract

The purpose of the study was to determine which factors correlate directly with response to vaccination in such a group of subjects with non-protective HI antibody titers before vaccination. Two vaccines were used, a subunit virus vaccine adjuvanted with MF59 and a split virus vaccine. The analysis indicated that immunization with vaccine adjuvanted with MF59 was an independent variable for immune response against A/H3N2 (OR: 3.51; 95% CI: 1.81-6.79) and B (OR: 2.31; 95% CI: 1.37-3.89). The results suggest that antibody response to vaccine is satisfactory in elderly people previously lacking a protective antibody titer, and that the adjuvanted vaccine reveals a better immunogenicity.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17082899     DOI： 10.1007/s10654-006-9071-4

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN： 0393-2990            Impact factor:   8.082


  8 in total

1.  Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.

Authors:  T Menegon; V Baldo; C Bonello; D Dalla Costa; A Di Tommaso; R Trivello
Journal:  Eur J Epidemiol       Date:  1999-07       Impact factor: 8.082

2.  A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

Authors:  Trang Vu; Stephen Farish; Mark Jenkins; Heath Kelly
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

3.  A history of influenza.

Authors:  C W Potter
Journal:  J Appl Microbiol       Date:  2001-10       Impact factor: 3.772

4.  Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

Authors:  W E P Beyer; A M Palache; G Lüchters; J Nauta; A D M E Osterhaus
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

5.  Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients.

Authors:  E J Remarque; J M de Jong; R J van der Klis; N Masurel; G J Ligthart
Journal:  Exp Gerontol       Date:  1999-01       Impact factor: 4.032

6.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

Review 7.  Haemagglutination-inhibiting antibody to influenza virus.

Authors:  J C de Jong; A M Palache; W E P Beyer; G F Rimmelzwaan; A C M Boon; A D M E Osterhaus
Journal:  Dev Biol (Basel)       Date:  2003

8.  Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature.

Authors:  W E Beyer; A M Palache; A D Osterhaus
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859
  8 in total
  5 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Authors:  Barbara Camilloni; Michela Basileo; Stefano Valente; Emilia Nunzi; Anna Maria Iorio
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-21

Review 4.  Quantitative review of antibody response to inactivated seasonal influenza vaccines.

Authors:  Jessica C Seidman; Stephanie A Richard; Cécile Viboud; Mark A Miller
Journal:  Influenza Other Respir Viruses       Date:  2011-06-13       Impact factor: 4.380

5.  Antibody response to influenza A(H1N1)pdm09 in vaccinated, serologically infected and unaffected pregnant women and their newborns.

Authors:  Rikke B Helmig; Rikke D Maimburg; Christian Erikstrup; Henriette S Nielsen; Olav B Petersen; Lars P Nielsen; Lone Hvidman; Jens E Veirum; Tine B Henriksen; Merete Storgaard
Journal:  Acta Obstet Gynecol Scand       Date:  2015-05-26       Impact factor: 3.636
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.